# To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

> **NCT03610880** · PHASE1 · COMPLETED · sponsor: **Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Chinese Volunteers

## Interventions

- **DRUG:** TG-2349 (400 mg) plus DAG181 (200 mg)
- **DRUG:** DAG181 (200 mg) plus TG-2349 (400 mg)

## Key facts

- **NCT ID:** NCT03610880
- **Lead sponsor:** Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2018-02-05
- **Final completion:** 2018-02-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610880, "To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03610880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*